Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$9.96 USD
+0.35 (3.64%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $9.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Tango Therapeutics, Inc. [TNGX]
Reports for Purchase
Showing records 1 - 20 ( 44 total )
Company: Tango Therapeutics, Inc.
Industry: Unclassified
TNG348 Development Discontinued; Modulating PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
TNG348 A No-Go; Remain Confident in PRMT5 Franchise
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Q1 Financials; Execution Across Pipeline, PRMT5 Program Update in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
We Eagerly Await Initial TNG908/TNG462 Data; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
We Eagerly Await Initial TNG908 Data; 4Q23 Financials; Adjusting PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Optimized Entry and Exit Levels for TNGX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
TNG908 Clinical Data Slated for 2024; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Preclinical Data For TNG348 Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
TNG908 Derisked by Competitor Data; Raising PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Tango Therapeutics, Inc.
Industry: Unclassified
Company: Tango Therapeutics, Inc.
Industry: Unclassified
This PRMT5i Data Deserves a PR; MRTX Data Validates TNG908, TNG462 Mechanism
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R